Customers buy finished medicines directly or through distributors and pay within one year after products ship or are delivered. The company also licenses product rights and can earn later sales-based milestones and royalties.
10-K for FY2025, filed Feb 27, 2026The Company’s performance obligation is the supply of finished pharmaceutical products to its customers. The Company’s customers consist…View ↗
Revenue is recognized when the Company transfers control of its products to the customer, which typically occurs at a point-in-time, upon…View ↗
The Company offers standard payment terms to its customers and has elected the practical expedient to not adjust the promised amount of…View ↗
From time to time, the Company may enter into arrangements where it licenses certain products to a third-party distributor. Licensing…View ↗
Revenue from sales-based milestones and royalties promised in exchange for a license of IP is recognized only when, or as, the later of…View ↗
10-K for FY2025, filed Feb 27, 2026
FY2025 revenue by reportable segment ↗$3B
10-K for FY2025, filed Feb 27, 2026
$3B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Affordable Medicines
Sold outright
10-K for FY2025, filed Feb 27, 2026 |
58%
FY2022: 65%
|
Affordable Medicines, FY2025
$1.7B Sources
|
Sold outright |
|
Specialty
Sold outright
10-K for FY2025, filed Feb 27, 2026 |
18%
FY2022: 17%
|
Specialty, FY2025
$528.5M Sources
|
Sold outright |
|
AvKARE
Sold outright
10-K for FY2025, filed Feb 27, 2026 |
25%
FY2022: 18%
|
AvKARE, FY2025
$744.7M Sources
|
Sold outright |
Most Affordable Medicines products go through wholesalers, group purchasing organizations, retail and mail-order pharmacies; sterile injectables and biosimilars also go through specialty distributors, with some direct sales to hospitals and institutions. Specialty representatives promote branded medicines to physicians, while AvKARE serves government agencies and retail and institutional buyers.
10-K for FY2025, filed Feb 27, 2026
Yes. It kept 2 cents of every revenue dollar as net income in FY2025 and turned 9 cents into free cash flow.
10-Q for Q3 FY2026, filed Nov 9, 2026
−$21.7MView ↗
10-Q for Q3 FY2026, filed Nov 9, 2026
Open tableView ↗
8-K, filed Aug 10, 2026
BRIDGEWATER, N.J., August 10, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today…View ↗
8-K, filed Jul 30, 2026
Net revenue $3.10 billion - $3.20 billion $3.05 billion - $3.15 billionView ↗
Growing. Revenue grew 44% in 4 years, from $2.1B in FY2021 to $3B in FY2025, about 10% a year.
Biosimilar portfolio
The older report described an initial oncology biosimilar portfolio; the latest report adds denosumab biosimilars and describes a broader set of commercially available biosimilars.
10-K for FY2022, filed Mar 3, 2023 10-K for FY2025, filed Feb 27, 2026Additionally, in 2022 we began to commercialize an initial portfolio of oncology biosimilars in the United States. Alymsys®, a biosimilar…View ↗
In 2022, we began to commercialize an initial portfolio of oncology biosimilars in the U.S. ALYMSYS®, a biosimilar referencing Avastin®…View ↗
Specialty products
The older report listed Rytary, Unithroid, and Lyvispah; the latest report also describes CREXONT and a Brekiya autoinjector in the Specialty portfolio.
10-K for FY2022, filed Mar 3, 2023 10-K for FY2025, filed Feb 27, 2026Our Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products, with…View ↗
Loading...